추천 제품
애플리케이션
Complement factor H (CFH) is a plasma regulator of the complement protein C3b in the alternative pathway of the complement system. Research has shown that binding of CFH is important for pathogenesis of group A streptococcus (GAS), and inhibition of this binding may be an effective management of GAS infections.
생화학적/생리학적 작용
Complement factor H plays an essential role in the homeostasis of the complement system and in preventing collateral damage to bystander cells and tissues by complement activation.
C3b-binding protein which regulates the formation and function of complement C3 and C5 convertases.
기타 정보
View more information on the complement pathway at www.sigma-aldrich.com/enzymeexplorer
면책조항
RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.
Storage Class Code
10 - Combustible liquids
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
시험 성적서(COA)
제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.
D T Fearon et al.
Proceedings of the National Academy of Sciences of the United States of America, 74(4), 1683-1687 (1977-04-01)
The surface of zymosan (Zy), by affording a protected microenvironment for C3b and the amplification convertase stabilized by properdin, P,C3b,Bb, shifts the alternative complement pathway from slow fluid phase turnover to the amplification phase of its expression. This mode of
Arife Uslu-Gökceoğlu et al.
The Turkish journal of pediatrics, 55(1), 86-89 (2013-05-23)
Atypical hemolytic uremic syndrome (aHUS) is a disease caused by pathologies in the alternative complement system. The prevalence of aHUS is 10% of all aHUS cases. The subgroup of aHUS designated as DEAP (DEficiency of CFHR Proteins and CFH Autoantibody
A Massart et al.
Acta clinica Belgica, 68(1), 9-14 (2013-05-01)
Atypical haemolytic uraemic syndrome (aHUS) results from uncontrolled complement system activation. Complement factor H gene mutations are common causes of aHUS. Plasmatherapy, including plasma infusions and/or plasma exchanges, has been tried in this setting with various successes. At present, we
Christoph Q Schmidt et al.
Journal of immunology (Baltimore, Md. : 1950), 190(11), 5712-5721 (2013-04-26)
Inadequate control of the complement system is the underlying or aggravating factor in many human diseases. Whereas treatment options that specifically target the alternative pathway (AP) of complement activation are considered highly desirable, no such option is available in the
Complement Factor H-ligand interactions: Self-association, multivalency and dissociation constants.
Perkins SJ., et al.
Immunobiol. (2011)
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.